Juventas Cell Therapy Ltd (JUVENTAS) was founded in June 2018 with its headquarter at China Central Place, Chaoyang District, Beijing, and a R&D and transformation base for immune cell therapeutic drugs in Tianjin Huayuan Industrial Park. As a biotechnology company specializing in discovery of innovative immune cell therapeutic drugs, JUVENTAS is committed to building a whole industry chain business for immune cell therapeutic drugs, including R&D, manufacturing, and the sales.
Relying on the preliminary technical achievements of the domestic first-class hematology hospital and hematology research institute, JUVENTAS has accelerated the transformation of research results of cell therapeutic drugs such as CAR-T.
It has been continuously integrating domestic and foreign technology, talents and funds since its foundation. At present, the company’s first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma. JUVENTAS has already built a GMP immune cell drug R&D transformation facility of 1400 square meters in Tianjin Huayuan Industrial Park, and there is a 7,000-square-meter production base for GMP immune cell drugs under construction as well.
With an efficient R&D transformation platform, the company is capable of introducing safe, effective and accessible high-quality cell therapy products to Chinese patients, who will definitely benefit from the manufacturing and quality systems of our meticulous cell therapy products!
Lü Lu LuCEO
Ph.D. in Hematology.Fujian Medical University
Exchange visitor at New York Medical College (NYMC)
•Hematologist, 11 years of experience
•10 years of experience in innovative drug development and new product strategic planning in the field of blood and oncology
•Worked in the R&D center, new product planning and marketing departments of multinational companies, such as Novartis, Roche, AstraZeneca and MSD
•Instrumental in the successful launch and market expansion of groundbreaking cancer products
Master of International Pharmaceutical Engineering Management.Peking University.
MBA, Maryville University St. Louis, USA
20 years of experience in corporate management, human resources and project management in the pharmaceutical industry.
Tomasz SosinowskiR&D Director
Ph.D. in Immunology.University of California, San Francisco (UCSF)
•10 years of experience in immune cell function and signaling pathway research
•Currently responsible for the development of CAR-T at the San Francisco R&D Center of Juventas
Zhang QiMedical Director
Ph.D. in Hematology, Institute of Hematology, Peking University People’s Hospital
• Clinician of Peking University People’s Hospital
• Clinical Medicine at Genzyme, Sanofi, CP Guojian and Genor Biopharma.
Sun JianhuiClinical Operation Director
Graduated from the College of Life Sciences of Nankai University
A former core leadership team member of the Pfizer (China) Clinical Trial Management Team, with extensive clinical trial experience in various fields and all phases
Deng YipingBiomarkers Development Director
Ph.D. in Pathology of the Joint training Project, Jilin University/University of California, San Diego
Former head of the Immuno-oncology diagnostic team of AstraZeneca.
Wang HaoRegulatory Affairs Director
Master of Tianjin University
More than 10 years of experience in drug registration of multinational pharmaceutical companies and successful submission and approval of multiple clinical approvals for Class 1 biopharmaceuticals.
Shi LinTechnical Director
Ph.D. in Internal Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College
10 years of experience in biological products development, transformation and quality management.
Wang YingQuality Assurance Director
More than 10 years of experience in multinational pharmaceutical companies, including years of quality management experience in GSK and Novozymes Biopharma.
Lu Guo QiuBeijing R&D Center Director
Ph.D. in Biochemistry and Molecular Biology, Peking Union Medical College
• Has been engaging in tumor cellular immunotherapy since graduation
• Rich experience in immune cell product development, laboratory management, GMP production, and quality control
• Currently in charge of the CAR-T product research and development
• Served as executive deputy general manager and technical director of CASI
Fu DingFinancial Director
China Certified Public Accountant (CPA) and Affiliate Member of AIA (AMIA)
• Engaged in finance for 20 years
• Years of financial management experience of retail groups and Internet entrepreneurial companies
• Experience in mergers and acquisitions, IPO, financing, etc.
Peng HuaMedical Manager
Ph.D. in Biochemistry and Molecular Biology, Peking Union Medical College (Chinese Academy of Medical Sciences)
• 5 years of experience in blood disease laboratory and blood transfusion department
• 3 years of experience in CAR-T industry
• Currently responsible for the development of clinical trial protocols and related medical affairs.